Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs NOV Inc. Common Stock (NOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs NOV Inc. Common Stock — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while NOV Inc. Common Stock trades at $18.75 (market cap $6.76B). The key difference: Ionis Pharmaceuticals Inc. Common Stock and NOV Inc. Common Stock are close in size by market cap, and NOV Inc. Common Stock pays a 1.9% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and NOV Inc. Common Stock for 6 Days on average.
| IONS | NOV | |
|---|---|---|
Market Cap | $7.04B | $6.76B |
Volume | 2,977,440 | 2,412,554 |
Sector | Health | Energy |
52-Week High | $86.50 | $21.71 |
52-Week Low | $42.38 | $12.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.60B | $7.92B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.
The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About NOV Inc. Common Stock
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →
